FTC crackdown on ‘bogus’ patents hits Novo’s Ozempic, GSK’s Trelegy Ellipta

Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the market entry of generic drugs.

This week, the Federal Trade Commission (FTC) sent warning letters to 10 drugmakers, disputing the accuracy of some 300 patent listings in the Food and Drug Administration’s so-called “Orange Book.”